SML2020

Atrasentan hydrochloride

≥98% (HPLC), ETA receptor antagonist, powder

• Sinónimos: (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid hydrochloride, 2R-(4-Methoxyphenyl)-4S-(1,3-benzodioxol-5-yl)-1-(N, N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid hydrochloride, A-147627 hydrochloride, ABT-627 hydrochloride
• Fórmula empírica (notación de Hill): C₂₉H₃₈N₂O₆ · HCl
• Número CAS: 195733-43-8
• Peso molecular: 547.08
• NACRES: NA.77
• UNSPSC Code: 12352200
• MDL number: MFCD13194884
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Propiedades

• Nombre del producto: Atrasentan hydrochloride, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: [H]Cl.CCCCN(CCCC)C(CN1C[C@H](C2=CC=C(OCO3)C3=C2)[C@@H](C(O)=O)[C@@H]1C4=CC=C(OC)C=C4)=O
• InChI: 1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1
• InChI key: IJFUJIFSUKPWCZ-SQMFDTLJSA-N

Descripción

General description

Atrasentan has also been used to treat cardiovascular disease.

Biochem/physiol Actions

Atrasentan is a selective endothelin ETA receptor antagonist with an IC50 of 0.2 nM for ETA compared to 190 nM for ETB receptors. It blocks blocks endothelin induced cell proliferation, and has been investigated as a possible treatment for prostate cancer, and more recently for therapy for diabetic kidney disease.

Selective endothelin ETA receptor antagonist

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3